Irritation and staining by dithranol (anthralin) and butantrone (10-butyryl dithranol): further short contact and tape stripping experiments. 1987

A Göransson

Ten psoriatics were tested with three concentrations of butantrone (0.66, 2.0 and 3.9%) on the healthy skin of the back and the irritant and staining reactions were compared with those produced by 0.1 and 0.5% dithranol, both in white petrolatum. Of the three test areas one was stripped before exposure to simulate the penetration of a psoriasis lesion, one after exposure to simulate posttreatment washing and one was unstripped. The contact times were 20 and 60 min. The degrees of erythema and staining, and the increase in skin blood flow were measured 1, 2, 3 and 7 days after application. Both dithranol concentrations produced a markedly stronger increase of blood flow and erythema than any of the butantrone concentrations and a clear dose response when the concentration was raised from 0.1 to 0.5%. Such a dose response was not clearly seen with butantrone. Staining with both dithranol and butantrone was minimal. Apparently, higher concentrations of butantrone than dithranol can be used in short contact therapy if cumulation of the drug can be excluded by a short contact time and careful removal of the surplus drug.

UI MeSH Term Description Entries
D007509 Irritants Drugs that act locally on cutaneous or mucosal surfaces to produce inflammation; those that cause redness due to hyperemia are rubefacients; those that raise blisters are vesicants and those that penetrate sebaceous glands and cause abscesses are pustulants; tear gases and mustard gases are also irritants. Counterirritant,Counterirritants,Irritant,Pustulant,Pustulants,Rubefacient,Rubefacients,Vesicant,Vesicants
D011565 Psoriasis A common genetically determined, chronic, inflammatory skin disease characterized by rounded erythematous, dry, scaling patches. The lesions have a predilection for nails, scalp, genitalia, extensor surfaces, and the lumbosacral region. Accelerated epidermopoiesis is considered to be the fundamental pathologic feature in psoriasis. Palmoplantaris Pustulosis,Pustular Psoriasis of Palms and Soles,Pustulosis Palmaris et Plantaris,Pustulosis of Palms and Soles,Psoriases
D012039 Regional Blood Flow The flow of BLOOD through or around an organ or region of the body. Blood Flow, Regional,Blood Flows, Regional,Flow, Regional Blood,Flows, Regional Blood,Regional Blood Flows
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000875 Anthralin An anthracene derivative that disrupts function and structure of MITOCHONDRIA and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS. 1,8-Dihydroxy-9-anthrone,Dithranol,1,8,9-Anthracenetriol,1,8-Dihydroxy-9(10H)-anthracenone,Anthraforte,Anthranol,Cignolin,Cygnoline,Dihydroxyanthranol,Dithrocream,Ditranol FNA,Lasan,Micanol,Psoradrate,Psoricrème,1,8 Dihydroxy 9 anthrone,FNA, Ditranol
D012867 Skin The outer covering of the body that protects it from the environment. It is composed of the DERMIS and the EPIDERMIS.
D012880 Skin Pigmentation Coloration of the skin. Skin Color,Skin Tone,Color, Skin,Colors, Skin,Pigmentation, Skin,Pigmentations, Skin,Skin Colors,Skin Pigmentations,Skin Tones,Tone, Skin,Tones, Skin
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

A Göransson
January 1986, International journal of clinical pharmacology research,
A Göransson
January 1989, Acta dermato-venereologica,
Copied contents to your clipboard!